Incyte Corporation (INCY) Reports 2013 Fourth-Quarter And Year-End Financial Results; Provides 2014 Financial Guidance; Updates Shareholders On Key Clinical Programs
2/12/2014 8:08:20 AM
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Corporation (Nasdaq: INCY) today reported 2013 fourth-quarter and year-end financial results, including revenue from Jakafi® (ruxolitinib), which is approved by the U.S. Food & Drug Administration (FDA) for the treatment of patients with intermediate or high-risk myelofibrosis (MF). The Company also provided 2014 financial guidance and highlighted multiple achievements in its clinical programs, including agreement with the FDA for a Special Protocol Assessment (SPA) for a registration trial of ruxolitinib in patients with advanced or metastatic pancreatic cancer.
Help employers find you! Check out all the jobs and post your resume.
comments powered by